NA
NAMSW
NewAmsterdam Pharma Co N.V.
$18.80
+4.50%
$2.2B
No data for this timeframe.
Vol
Market Cap$2.2B
Cap SizeMid Cap
SEC Reports3
Recent Activity
Jun 3, 2026
other
NewAmsterdam Pharma Announces Upcoming Presentations at the National Lipid Association (NLA) 2026 Scientific Sessions
<p>NAARDEN, The Netherlands and MIAMI, June 03, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Compa
Jun 3, 2026
SEC
NewAmsterdam Pharma filed an 8-K reporting the results of its 2026 annual general meeting, where shareholders approved t
8-K — Impact 3/10
May 7, 2026
SEC
NewAmsterdam Pharma reported Q1 2026 revenue of $3.0M (flat YoY) and a net loss of $48.4M, widening from $39.5M. The key
8-K — Impact 6/10
Apr 24, 2026
SEC
NewAmsterdam Pharma's Chief Accounting Officer, Louise Kooij, will depart on August 31, 2026, with a separation agreemen
8-K — Impact 3/10
Latest Reports
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
3 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 0 mixed, 2 neutral. Avg impact: 4.0/10.
NEUTRAL
8-K
3/10
NewAmsterdam Pharma filed an 8-K reporting the results of its 2026 annual general meeting, where sha
Jun 3, 2026
BULLISH
8-K
6/10
NewAmsterdam Pharma reported Q1 2026 revenue of $3.0M (flat YoY) and a net loss of $48.4M, widening
May 7, 2026
NEUTRAL
8-K
3/10
NewAmsterdam Pharma's Chief Accounting Officer, Louise Kooij, will depart on August 31, 2026, with a
Apr 24, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | -92.0% | — |
| Next Q 2026-09-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | 2050.3% | — |
| Current FY 2026-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | 22.5% | — |
| Next FY 2027-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.1B | 466.0% | — |
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 3, 2026
other
NewAmsterdam Pharma Announces Upcoming Presentations at the National Lipid Association (NLA) 2026 Scientific Sessions
<p>NAARDEN, The Netherlands and MIAMI, June 03, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Co
May 28, 2026
other
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June
<p>NAARDEN, the Netherlands and MIAMI, May 28, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Com
May 11, 2026
other
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in May
<p>NAARDEN, the Netherlands and MIAMI, May 11, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Com
May 7, 2026
earnings
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
<p align="center"><em>– Decisions on regulatory approval from EMA, UK, and Switzerland for obicetrapib and obicetrapib/ezetimibe fixed</em><em>-</em><
May 1, 2026
other
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p>NAARDEN, the Netherlands and MIAMI, May 01, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Com
Apr 8, 2026
earnings
NewAmsterdam Pharma to Present at the 25th Annual Needham Virtual Healthcare Conference
<p>NAARDEN, the Netherlands and MIAMI, April 08, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “C
Apr 2, 2026
other
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p>NAARDEN, the Netherlands and MIAMI, April 02, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “C
Mar 6, 2026
other
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p>NAARDEN, the Netherlands and MIAMI, March 06, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “C